Status:
TERMINATED
99mTc-MIBI SPECT/CT in Breast Malignancy
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborating Sponsors:
University of Western Ontario, Canada
Conditions:
Breast Cancer
Eligibility:
FEMALE
25-90 years
Phase:
NA
Brief Summary
99mTc-SestaMIBI mammoscintigraphy (MMS) may be used in patients with locally advanced breast cancer (LABC) scheduled for neoadjuvant chemotherapy. MMS may be performed for 1) nodal staging of axillary...
Detailed Description
99mTc-SestaMIBI is a lipophylic cation as many cytotoxic chemotherapy drugs (i.e. anthracyclines, inhibitor of topoisomerase II, antimicrotubule, vinca alkaloids, inhibitors of DNA replication) accumu...
Eligibility Criteria
Inclusion
- Patients with histologically proven breast cancer
- Patients with locally advanced breast cancer (stages T2-4 N0-3 M0)
- Patients scheduled for neoadjuvant chemotherapy
- Patients scheduled for radical modified mastectomy
- Patients with no physical and/or psychological contraindications
- Patients with no recent nuclear medicine study using long-lived isotopes (i.e. 67Ga, 111In, 131I) within the 48 hour preceding the mammoscintigraphy
Exclusion
- Patient with no histologically proven breast cancer
- Patients with early stage T1 breast cancer
- Patients who are not candidates for neoadjuvant chemotherapy
- Patients who are not surgical candidates
- Patients with physical and/or psychological contraindications
- Pregnant or breast feeding patients
- Patients with a recent nuclear medicine study using long-lived isotopes (i.e. 67Ga, 111In, 131I) within the 48 hour preceding the mammoscintigraphy
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00804544
Start Date
September 1 2008
End Date
January 1 2010
Last Update
March 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
South Street Hospital - Department of Nuclear Medicine
London, Ontario, Canada, N6A 4G5